Depression is an important global public health problem due to its relatively high lifetime prevalence and significant disability caused by it. The present study was conducted to compare improvement in disability outcome by Amisulpride and Escitalopram among depression patients using WHO-Disability Assessment Schedule (WHO-DAS).
Introduction
Depression is a commonly occurring, serious, recurrent disorder linked to diminished role functioning and quality of life, medical morbidity, and mortality [1] . The World Health Organization (WHO) has ranked depression the 4th leading cause of disability worldwide and projects that by 2020, it will be the second leading cause. The WHO defines depression as a pessimistic sense of inadequacy and a despondent lack of activity. The accompanying signs include psychomotor retardation or at times, withdrawal from interpersonal contact and vegetative symptoms such as anorexia and insomnia. Depression is associated with marked personal, social and economic morbidity affecting 9.5% of population worldwide [2] . First-line pharmacotherapy for depressive disorders is typically chosen from among the "newer antidepressants"-either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) [3] . Escitalopram were given tablet Escitalopram10 mg/day orally. The efficacy of the drugs was calculated by Hamilton depression rating scale (HAM-D). The improvement in functional outcome was compared between the two groups by using WHODisability Assessment Schedule (WHO-DAS). Drug compliance was monitored rigorously by providing drug calendars where time of medicines were specified daily but no drug blood levels were monitored due to lack of any such facility locally. The patients were followed up at 4, 8 and 15 weeks. The patients were contacted telephonically and reminded about their follow ups. Adverse drug reactions were monitored at every follow up. Appropriate statistical tools using Graph PadInstat 3.0 were used for analysis. p value < 0.05 was considered significant.
Results
Out of a total of 117 patients which were included in the study, 18 patients dropped out from the study due to varying reasons: 6 patients were lost to follow up, 6 patients were lost due to figure 2) . Intragroup comparison was done between baseline and 15 weeks which was highly significant in both the groups (p<0.0001) (figure 2). Intergroup comparison at the end of study was insignificant (p>0.05) (figure 2).
Figure 2: Comparison of WHO-DAS between the two groups Discussion
In the present study, there was a higher prevalence of depression in females which was in accordance with previous studies by Ramachandran et al depicting that women were more commonly suffering from depression [10] . The greater prevalence of depression among women is not fully understood, although potential contributors include different responses to stressful life events, genetic predisposition and hormonal differences [11] . The mean age in our study was 46.84±1.1years which was comparable with previous studies by Dutta et al where incidence of depression was seen in 30-51 years age group [12] . More depression patients were seen in rural areas as compared to urban areas in the present study. This was comparable with previous studies by Paritala et al, where rural back ground subjects were found to be somatising more than the urban subjects [13] . In our study more number of literates were suffering from depression which was comparable with previous study by Paritala et al [13] . A comparative evaluation of Escitalopram and Amisulpride was done in depression patients by measuring improvement in functional outcome using WHO Disability Assessment Schedule in this 15-week study. Escitalopram is an allosteric selective serotonin reuptake inhibitor (SSRI) with some indication of superior efficacy in the treatment of major depressive disorders. The results of our study revealed highly significant improvement in HAM-D in depressive patients over the study period. Intragroup comparison was made between baseline and 15 weeks in Escitalopram group and highly significant improvement was seen (p<0.0001). This was comparable with previous studies where efficacy of Escitalopram has been proven [14] . Amisulpride, a selective D2/D3 receptor second generation antipsychotic is indicated for the treatment of acute and chronic schizophrenia [15] . The presumed selectivity of amisulpride for D2 and D3 dopamine receptors has led to the prevailing hypothesis that modulation of dopaminergic signaling is responsible for its antidepressant efficacy. In the present study, the antidepressant effect of Amisulpride was compared at baseline and at 15 weeks in depressive patients and highly significant improvement was seen (p<0.0001). This was comparable with previous studies by Ravizza L et al where antidepressant role of amisulpride has been proven [16] . Amisulpride has some selectivity for presynaptic dopamine autoreceptors, and exhibits limbic versus striatal selectivity, particularly at low doses, and it has been suggested that this might account for its therapeutic profile [18] . The improvement in functional impairment was measured by WHO-DAS. In the present study, highly significant improvement was seen in both Escitalopram and Amisulpride groups. Previous studies by Kessler RC et al have shown improvement in WHO disability assessment scale with escitalopram [18] . A study by Gutierrenz F et al has shown improvement in WHO-DAS by second generation antipsychotics proving that patients who take medications that are efficacious and acceptable have a better chance of achieving superior functional improvements compared to those who take agents that are less efficacious and/or not as well accepted [19] . At the end of the study period, intergroup comparison was made between Escitalopram group and Amisulpride group which revealed no significant difference (p<0.05), indicating both the drug were equally efficacious in improving disability score in depression patients. 
